0001140361-18-027787.txt : 20180607 0001140361-18-027787.hdr.sgml : 20180607 20180607202245 ACCESSION NUMBER: 0001140361-18-027787 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20180605 FILED AS OF DATE: 20180607 DATE AS OF CHANGE: 20180607 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HERON ELAINE J CENTRAL INDEX KEY: 0001235471 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-26727 FILM NUMBER: 18887894 MAIL ADDRESS: STREET 1: 6 STONEGATE RD CITY: PONTOLA VALLEY STATE: CA ZIP: 94028 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOMARIN PHARMACEUTICAL INC CENTRAL INDEX KEY: 0001048477 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 680397820 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 105 DIGITAL DRIVE CITY: NOVATO STATE: CA ZIP: 94949 BUSINESS PHONE: 4155066700 MAIL ADDRESS: STREET 1: 105 DIGITAL DRIVE CITY: NOVATO STATE: CA ZIP: 94949 4 1 doc1.xml FORM 4 X0306 4 2018-06-05 0 0001048477 BIOMARIN PHARMACEUTICAL INC BMRN 0001235471 HERON ELAINE J C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO CA 94949 1 0 0 0 Common Stock 2018-06-05 4 A 0 4300 0 A 42685 D Restricted stock units granted on June 5, 2018. Price not applicable. /s/ Eric Fleekop, Attorney-in-Fact 2018-06-07 EX-24 2 poa_heron.htm
POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of G. Eric Davis, Laura Randall Woodhead, and Eric Fleekop, signing singly, the undersigned’s true and lawful attorney-in-fact to:

(1)        execute for and on behalf of the undersigned, in the undersigned’s capacity as an officer and/or director of BioMarin Pharmaceutical Inc. (the “Company”), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;

(2)        do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

(3)        take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted.  The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 5th day of June, 2018.

/s/ Elaine J. Heron  
Elaine J. Heron, Ph.D.
  
 
 
- 1 -